By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Enterprise Replace Topline Knowledge from OVATION 2 Trial Anticipated in Mid-2024 Imunon, Inc. (NASDAQ:IMNN)...